EFPIA Unveils Nathalie Moll as New Director General
The EFPIA has revealed the appointment of Nathalie Moll as its new director general.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has revealed the appointment of Nathalie Moll as its new director general. Currently secretary general of the European Association for Bioindustries (EuropaBio), she will join EFPIA in April 2017.
Commenting on the appointment, Joe Jimenez, President of EFPIA, said “Nathalie has an excellent track record of leadership and engagement across the life science sector. We are confident she is the right person to lead EFPIA, working with stakeholders to address the challenges faced by healthcare systems in Europe.”
Moll became secretary general of EuropaBio. Moll, currently EuropaBio’s director for agricultural biotechnology in April 2010, replacing Willy De Greef.
“I am delighted to be joining EFPIA at a time when pharmaceutical innovation is having such a dramatic effect on the lives of patients across Europe,” she said. “I look forward to working with EFPIA Members, staff and the wider research, healthcare and policy community to foster an environment that supports continued innovation and drives better outcomes for patients.”
Eric Cornut will continue to lead EFPIA as interim director general until Moll joins the organisation in April.
Philip Ward is the European Editor for Applied Clinical Trials
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
